Anti-Human CD37 Recombinant Antibody (Lilotomab) (CAT#: TAB-467CQ)

Figure 1 Toxicity of Lilotomab.

Lack of correlation between RM dose derived by surrogate method and reduction in thrombocyte (A) and neutrophil (B) counts demonstrates that this non–imaging-based method is unfit to predict marrow toxicity for 177Lu-lilotomab satetraxetan therapy.

Blakkisrud, J., Løndalen, A., Dahle, J., Turner, S., Holte, H., Kolstad, A., & Stokke, C. (2017). Red marrow–absorbed dose for non-hodgkin lymphoma patients treated with 177lu-lilotomab satetraxetan, a novel anti-cd37 antibody–radionuclide conjugate. Journal of Nuclear Medicine, 58(1), 55-61.

Figure 2 DNA content and DNA damage in U-2932 and RIVA cells after treatment with 177Lu-lilotomab satetraxetan.

Cells were treated with indicated doses of 177Lu-lilotomab satetraxetan [600 MBq/mg] for 18 hours, washed and fixated. DNA content (FxCycleFarRed) and DNA damage (anti-P-g-H2AX) were assessed by flow cytometry.

Rødland, G. E., Melhus, K., Dahle, J., Syljuåsen, R., & Patzke, S. (2018). Cell Cycle Kinase Inhibitors Potentiate the Effect of 177lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines.

Figure 3 ADCC induction by (A) obinutuzumab and (B) rituximab in Raji 2R cells relative to untreated Raji cells of corresponding mAb exposure.

Statistical significance by 2-tailed t-test where *** p< 0.001 and ** p< 0.01 (N=3).

Marion M. Malenge, Sebastian Patzke, Anne Hansen Ree,… & and Ada H. V. Repetto-Llamazares. 177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab and obinutuzumab in non-Hodgkin’s lymphoma.

Figure 4 177Lu-lilotomab satetraxetan and the increase was dependent on the concentration of 177Lu-lilotomab satetraxetan.

Rituximab binding presented as mean ± SD of median fluorescence intensity (MFI) plotted against escalating concentrations of mAbs at 3 and 6 days in Raji 2R and in Raji cells (N=3).

Marion M. Malenge, Sebastian Patzke, Anne Hansen Ree,… & and Ada H. V. Repetto-Llamazares. 177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab and obinutuzumab in non-Hodgkin’s lymphoma.